RFR and FFR for the the Prediction of Post-PCI Results (PICIO)
Primary Purpose
Coronary Artery Disease
Status
Recruiting
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
RFR
FFR
Sponsored by
About this trial
This is an interventional diagnostic trial for Coronary Artery Disease focused on measuring stent, coronary stenosis, Angina
Eligibility Criteria
Inclusion Criteria:
Patients must meet ALL of the inclusion criteria:
- Clinical indication for elective percutaneous coronary intervention of a stenosis >40% and <90% with clinical indication to percutaneous intervention (PCI) requiring functional assessment. Note: the decision to perform functional assessment will have to be taken before, and independently of, the inclusion and randomization in the study.
- Documented heart team (when applicable, as per guidelines) decision for revascularization via PCI
- Patient ≥18 years old
Exclusion Criteria:
Patients will be excluded if ANY of the exclusion criteria is met:
- Cardiogenic shock
- Any contraindication to PCI according to guidelines
- Presence of a coronary artery bypass grafting (CABG) in the territory under study
- Culprit vessels in patients with ST-segment elevation myocardial infarction (STEMI)
- TIMI (Thrombolysis in Myocardial Infarction) flow grade < 3
- Lesion severity > 90% by visual assessment
- Presence of thrombus
- Participation in another randomized interventional study
- Patient unable to give informed consent
- Women of child-bearing potential or lactating
Sites / Locations
- Center of Cardiology, Cardiology I, university hospital MainzRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
RFR: resting full-cycle ratio
FFR: fractional flow reserve
Arm Description
RFR will be used to drive PCI
FFR will be used to drive PCI
Outcomes
Primary Outcome Measures
Absolute difference between RFR observed and expected as compared to FFR observed versus expected.
Comparison of |RFRexp-RFRobs| vs. |FFRexp-FFRobs| (i.e., absolute differences between expected and observed final hemodynamic result) RFRexp and FFRexp are defined as (RFRbas plus RFRGrad) and (FFRbas plus FFRGrad)
Secondary Outcome Measures
Full Information
NCT ID
NCT04417634
First Posted
June 1, 2020
Last Updated
September 26, 2023
Sponsor
Johannes Gutenberg University Mainz
1. Study Identification
Unique Protocol Identification Number
NCT04417634
Brief Title
RFR and FFR for the the Prediction of Post-PCI Results
Acronym
PICIO
Official Title
Pullback wIth Resting Full-Cycle Flow ratIO or Fractional Flow Reserve for the Prediction of Post-PCI Hemodynamic Outcomes. A Study in Patients With Diffuse Coronary Artery Disease
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 10, 2020 (Actual)
Primary Completion Date
June 10, 2025 (Anticipated)
Study Completion Date
June 10, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johannes Gutenberg University Mainz
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to record hemodynamic pullback information using continuous resting full-cycle flow ratio (RFR) and fractional flow reserve (FFR) in patients with diffuse coronary artery disease. The capacity of the two indexes to predict the hemodynamic outcome after stenting will be compared.
Goals of the study are:
To study the accuracy of RFR/FFR gradients in predicting the change in whole-vessel RFR/FFR after PCI.
To identify a threshold in the RFR/FFR gradient that is predictive of pathological RFR/FFR also after the PCI of the first lesion.
Detailed Description
The study of the hemodynamic relevance of coronary stenoses is a well-validated method to identify coronary lesions to be treated. A number of studies show that FFR-guided PCI is superior to angiography guided PCI2-4. The achievement of maximal hyperemia is a prerequisite for FFR measurements. Hyperemia is usually achieved with the intravenous or intracoronary infusion of adenosine, which requires time and is potentially associated with discomfort for the patient. To avoid this, resting indexes have been developed. The instantaneous flow reserve (iFr) was the first of these indexes, and two large studies have shown that this parameter is non-inferior to FFR in terms of patient prognosis5. More recently, a number of other parameters have been developed, among which the RFR (resting flow ratio), which can be measured with the same intracoronary wire as the FFR and therefore requires no additional procedures. Studies show that these methods are equivalent6. The advantage of these resting indexes (which are all included in the most recent AHA/ACC guidelines7, 8), is that they do not require hyperemia. This might represent a particular advantage in the setting of tandem stenoses or diffuse disease. Since hyperemic flow in a vessel is limited by each one of the stenoses present in that vessel, each individual stenosis limits the capacity of FFR to assess the hemodynamic relevance of the other ones. In other words, invasive measurements of coronary hemodynamics using FFR in the setting of diffuse or tandem lesions are complicated by the fact that maximal hyperemia cannot be achieved, which limits the capacity of FFR to assess the hemodynamic relevance of individual focal stenoses. In this setting, the usual binary system (FFR < or > 0.80) cannot be easily applied.
This limitation is independent of the sequence of the stenoses: proximal lesions limit the reliability of FFR measurements in distal stenoses and vice versa (as long as no significant side branches are present between the two lesions). Since hyperemic flow declines significantly as soon as a 50% reduction in lumen diameter is present, even apparently non-relevant lesions may compromise any assessment based on hyperemia. This phenomenon, called hemodynamic interdependence of stenoses under conditions of hyperemia represents a significant limitation that applies to FFR but not to hyperemia-free indexes.
In order to address this issue in routine practice, FFR is measured first, then a pullback is performed and the lesion/segment where the pullback identifies the highest gradient is treated first. The removal of this stenosis increases maximal achievable hyperemic flow, thus increasing the significance of the remaining lesions. FFR is then measured again to test the hemodynamic significance of the other stenoses at a higher level of hyperemia. The capacity of FFR to predict whether removal of the first stenosis will be associated with the normalization of FFR is very limited, which requires that FFR be measured multiple times, prolonging the procedure and increasing the discomfort for the patient.
When studying coronary stenoses, the advantage of resting hemodynamic indexes is that non-critical stenoses (ie below 90%) do not modify resting blood flow. Because resting flow is more constant, and the effect of PCI is minimal, resting pressure changes measured across sequential lesions are likely to be more predictable.The hypothesis of the study is that, as compared to FFR, RFR will provide a better estimate of post-PCI hemodynamic outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
stent, coronary stenosis, Angina
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
The study is a single-center, randomized superiority trial to compare two strategies for the assessment of the hemodynamic relevance of coronary lesions.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
RFR: resting full-cycle ratio
Arm Type
Experimental
Arm Description
RFR will be used to drive PCI
Arm Title
FFR: fractional flow reserve
Arm Type
Active Comparator
Arm Description
FFR will be used to drive PCI
Intervention Type
Diagnostic Test
Intervention Name(s)
RFR
Intervention Description
Measurement of resting flow ratio
Intervention Type
Diagnostic Test
Intervention Name(s)
FFR
Intervention Description
Measurement of fractional flow reserve
Primary Outcome Measure Information:
Title
Absolute difference between RFR observed and expected as compared to FFR observed versus expected.
Description
Comparison of |RFRexp-RFRobs| vs. |FFRexp-FFRobs| (i.e., absolute differences between expected and observed final hemodynamic result) RFRexp and FFRexp are defined as (RFRbas plus RFRGrad) and (FFRbas plus FFRGrad)
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must meet ALL of the inclusion criteria:
Clinical indication for elective percutaneous coronary intervention of a stenosis >40% and <90% with clinical indication to percutaneous intervention (PCI) requiring functional assessment. Note: the decision to perform functional assessment will have to be taken before, and independently of, the inclusion and randomization in the study.
Documented heart team (when applicable, as per guidelines) decision for revascularization via PCI
Patient ≥18 years old
Exclusion Criteria:
Patients will be excluded if ANY of the exclusion criteria is met:
Cardiogenic shock
Any contraindication to PCI according to guidelines
Presence of a coronary artery bypass grafting (CABG) in the territory under study
Culprit vessels in patients with ST-segment elevation myocardial infarction (STEMI)
TIMI (Thrombolysis in Myocardial Infarction) flow grade < 3
Lesion severity > 90% by visual assessment
Presence of thrombus
Participation in another randomized interventional study
Patient unable to give informed consent
Women of child-bearing potential or lactating
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tommaso Gori
Phone
+491721052846
Email
tomgori@hotmail.com
Facility Information:
Facility Name
Center of Cardiology, Cardiology I, university hospital Mainz
City
Mainz
State/Province
Rheinland-Pfalz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tommaso Gori, Prof Dr, PhD
Phone
+49 (0) 6131 17 2729
Email
tommaso.gori@unimedizin-mainz.de
First Name & Middle Initial & Last Name & Degree
Tommaso Gori, Prof Dr, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
RFR and FFR for the the Prediction of Post-PCI Results
We'll reach out to this number within 24 hrs